Unknown PHASE2 INTERVENTIONAL 1-arm NCT04457869

A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

A Phase 2, Open-label, Single-arm, Multicenter Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)

Sponsor: Shandong New Time Pharmaceutical Co., LTD

Conditions Primary Central Nervous System Lymphoma Secondary Central Nervous System Lymphoma

Interventions F520

Updated 6 times since 2020 Last updated: Oct 19, 2020 Started: Nov 1, 2020 Primary completion: Jul 31, 2022 Completion: Jan 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Primary Central Nervous System Lymphoma and Secondary Central Nervous System Lymphoma, this trial is ongoing. The trial is conducted by Shandong New Time Pharmaceutical Co., LTD and has accumulated 6 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Feb 2023 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status
Jan 2021 — Feb 2023 [monthly]

Not Yet Recruiting PHASE2
Nov 2020 — Jan 2021 [monthly]

Not Yet Recruiting PHASE2

▶ Show 1 earlier version

Aug 2020 — Nov 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong New Time Pharmaceutical Co., LTD

Data source: Shandong New Time Pharmaceutical Co., LTD

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.